Skip to content

Lisocabtagene maraleucel

Breyanzi (lisocabtagene maraleucel) is a gene pharmaceutical. Lisocabtagene maraleucel was first approved as Breyanzi on 2021-02-05. It is used to treat b-cell lymphoma in the USA.
Trade Name Breyanzi
Common Name Lisocabtagene maraleucel
Indication b-cell lymphoma
Drug Class Antineoplastic
Lisocabtagene maraleucel
Get full access now